AHO0802

antibody from Invitrogen Antibodies

Targeting: EIF2S1 EIF-2alpha, EIF2, EIF2A

Provider product page for AHO0802

Western blot

Immunocytochemistry

Immunoprecipitation

Immunohistochemistry

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [20]
Comments [0]
Validations
Immunocytochemistry [1]
Flow cytometry [1]
Other assay [20]

Submit

Product number: AHO0802 - Provider product page
Provider: Invitrogen Antibodies
Product name: EIF2S1 Monoclonal Antibody (EIF2-alpha)
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Description: This antibody recognizes the alpha subunit of eukaryotic translation initiation factor 2 (EIF2-alpha). Recommended positive control are human Jurkat, CEM, and HeLa cells; mouse 3T3L1 cells; and rat PC-12 cells.
Reactivity: Human, Mouse, Rat
Host: Mouse
Isotype: IgG
Antibody clone number: EIF2-alpha
Vial size: 100 µg
Concentration: 0.5 mg/mL
Storage: -20°C

EIF2S1 protein structure - AHO0802 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5. Association of G-actin with PPP1R15 regulates eIF2alpha phosphatase activity. ( A ) Immunoblot for phosphorylated eIF2alpha (P-eIF2alpha), total eIF2alpha, and actin. Wild-type (WT) mouse embryonic fibroblasts (MEF) were treated with jasplakinolide 1 uM for the indicated times. Lysates were subjected to sedimentation assay and immunoblot for G-actin in the supernatant (G) or F-actin in the pellet (F). ( B ) Immunoblot for phosphorylated eIF2alpha (P-eIF2alpha), total eIF2alpha, and actin. WT MEFs were treated with the indicated concentrations of jasplakinolide for 1 hr. Lysates were analysed as in ' A '. ( C ) Immunoblot for phosphorylated eIF2alpha (P-eIF2alpha), total eIF2alpha, and PPP1R15A. WT MEFs were treated with thapsigargin 400 nM for the indicated times, without or with jasplakinolide 1 uM. ( D ) Immunoblot for P-eIF2alpha and PPP1R15A (hR15A). GFP-hPPP1R15A Tet-On HeLa cells were treated with doxycycline to induce transgene expression and then with thapsigargin 400 nM for the indicated times. Cells were co-treated with jasplakinolide or latrunculin B 1 uM or vehicle as indicated. Accompanying graphs show means +-SEM of n = 3 independent repeats. DOI: http://dx.doi.org/ Figure 5--figure supplement 1. Immunoblot for phosphorylated eIF2alpha (P-eIF2alpha), total eIF2alpha and PPP1R15A. WT MEFs were treated with thapsigargin 400 nM for the indicated times, without or with latrunculin B 1 uM. DOI: http://dx.doi.org/

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6. Jasplakinolide diminishes eIF2alpha phosphatase activity in vivo. ( A ) Immunoblot for phosphorylated eIF2alpha (P-eIF2alpha), total eIF2alpha, and ATF4. Gcn2 -/- MEFs were pre-treated with thapsigargin 300 nM for 30 min to induce eIF2alpha phosphorylation and ATF4 protein levels. GSK2606414A at 2 uM was then added for the indicated times. Protein lysates were analysed by SDS-PAGE and subjected to immunoblot. ( B ) Quantification of ' A ' using ImageJ software. Mean +- SEM of n = 3 independent repeats. ( C ) Immunoblot for phosphorylated eIF2alpha (P-eIF2alpha) and total eIF2alpha. MEFs of the indicated genotypes were treated with or without jasplakinolide 1 uM for 1 hr. Protein lysates were analysed by SDS-PAGE and subjected to immunoblot. DOI: http://dx.doi.org/ Figure 6--figure supplement 1. Immunoblot for P-eIF2alpha, total eIF2alpha, and ATF4 (specific band marked with an asterisk) in lysates of wild type (WT) or eIF2alpha AA MEFs following treatment with thapsigargin 300 nM for 4 hr and/or jasplakinolide 1 uM for 4 hr. DOI: http://dx.doi.org/

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7. Actin associates with PPP1R15B to alter the level of eIF2alpha phosphorylation. ( A ) Immunoblot for GFP and actin of HEK293T cell lysates expressing either GFP or GFP-PPP1R15B. Upper two panels indicate proteins immunoprecipitated by anti-GFP beads. Lower panel shows 2% of input lysate. ( B ) Immunoblot for P-eIF2alpha, total eIF2alpha, and PPP1R15A of lysates from WT or Ppp1r15b tm1Dron/tm1Dron MEFs treated for 1 hr with thapsigargin 400 nM, jasplakinolide 1 uM or both. ( C ) Immunoblot for phosphorylated eIF2alpha (P-eIF2alpha), total eIF2alpha and actin. Ppp1r15a tm1Dron/tm1Dron MEFs were treated with jasplakinolide 1 uM for the indicated times. Lysates were subjected to sedimentation assay and immunoblot for G-actin in the supernatant (G) or F-actin in the pellet (F). ( D ) Immunoblot for phosphorylated eIF2alpha (P-eIF2alpha), total eIF2alpha, and actin. Ppp1r15a tm1Dron/tm1Dron MEFs were treated with the indicated concentrations of jasplakinolide for 1 hr. Lysates were analysed as in ' C '. Accompanying graphs show mean +- SEM of n = 3 independent repeats. DOI: http://dx.doi.org/

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 8. Association of actin with PPP1R15A promotes eIF2alpha phosphatase activity in vitro. ( A ) Silver-stained SDS-PAGE or GFP-affinity purified PPP1R15A-GFP (hR15-GFP) and associated proteins. Asterisks signify identity confirmed by mass spectrometry. Purified complex incubated with phosphorylated recombinant eIF2alpha N-terminal lobe (eIF2alpha) for incubated time. Note size shift corresponds to dephosphorylation. ( B ) Quantification of ' A ' using ImageJ software. Mean +- SEM. p value calculated by two-way ANOVA, n = 3. ( C ) Immunoblot for PPP1R15A and eIF2alpha of HEK293T cells expressing hPPP1R15A-GFP (hR15A-GFP). Treated with cycloheximide 50 uM for indicated times. ( D ) Quantification of ' C '. Mean +- SEM, n = 3. DOI: http://dx.doi.org/

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 9. Localised changes in the polymeric status of actin modulate the sensitivity of the ISR. ( A ) Fluorescence microscopy image of Flp-In T-REx HEK293 cells treated with 1 ug/ml doxycycline for 12 hr to express either ER membrane-localised GFP (GFP-R15B 1-146) or ER membrane-localised GFP-mDia2 fusion (GFP-R15B 1-146_mDia2) then fixed and stained with Alexa-Fluor 568 phalloidin and imaged by confocal microscopy. Bar = 5 um. ( B ) Immunoblot for GFP and ATF4 in lysates of GFP-R15B 1-146 or GFP-R15B 1-146_mDia2 Flp-In T-REx HEK293 cells following treatment with doxycycline (Dox) 0.1 ug/ml for indicated times or with ISRIB 100 nM and or thapsigargin 300 nM for 4 hr. Immunoreactivity to ATF4 was quantified using ImageJ software (ATF4 Intensity). Proteins of the expected sizes are marked with a solid triangle GFP-R15B 1-146_mDia2 or an open triangle GFP-R15B 1-146. ( C ) Immunoblot for P-eIF2alpha, total eIF2alpha, and puromycin in lysates of GFP-R15B 1-146 or GFP-R15B 1-146_mDia2 Flp-In T-REx HEK293 cells following pre-treatment--if indicated with doxycycline (Dox) 0.1 ug/ml for 10 hr followed by treatment with tunicamycin 2.5 ug/ml for indicated times. 10 min prior to harvesting, puromycin was added to the culture medium at a final concentration of 10 ug/ml. Immunoreactivity to puromycin within lysates served as a marker of protein translation and was quantified using ImageJ software (Puromycin intensity). Accompanying graphs of mean +- SEM of n = 3 independent repeats. DO

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5--figure supplement 1. Immunoblot for phosphorylated eIF2alpha (P-eIF2alpha), total eIF2alpha and PPP1R15A. WT MEFs were treated with thapsigargin 400 nM for the indicated times, without or with latrunculin B 1 uM. DOI: http://dx.doi.org/

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6--figure supplement 1. Immunoblot for P-eIF2alpha, total eIF2alpha, and ATF4 (specific band marked with an asterisk) in lysates of wild type (WT) or eIF2alpha AA MEFs following treatment with thapsigargin 300 nM for 4 hr and/or jasplakinolide 1 uM for 4 hr. DOI: http://dx.doi.org/

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: RNA immunoprecipitation (RIP) of EIF2A was performed on K562 cells. Antigen-antibody complexes were formed by incubating approximately 500 µg whole cell lysate with 5 µg of monoclonal EIF2A antibody (Product # AHO0802( rotating 60 min at RT. The immune complexes were captured on 625 µg of anti-mouse coated Dynabeads (Product # 11202D), washed extensively, and eluted with NuPAGE™ LDS Sample Buffer (Product # NP0007). Samples were resolved onto NuPAGE™ 4-12% Bis-Tris gel (Product # NP0335BOX). Lanes 1 and 3 are input and lanes 2 and 4 are IP. Proteins were transferred to PVDF membrane (Product # IB23001). Membrane was blocked in 5% milk. Target was detected using a EIF2A monoclonal antibody (Product # AHO0802) at a dilution of 1:2000, followed by a 1:4000 dilution of secondary antibody. Chemiluminescent detection was performed using ECL Western Blotting Substrate (Product # 32106). Data courtesy of the Yeo lab as part of the ENCODE project (www.encodeproject.org).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 Cytosolic DELE1 physically interacts with and activates HRI. (a) Immunoblot of biochemical fractionations of cells stably expressing DELE1-mClover treated with 1.25 ng/mL oligomycin (Oli) for 16 h where indicated. Left , representative immunoblot of the cytosolic (C) and mitochondrial (M) fractions. LonP1 and cytochrome c were probed as mitochondrial markers. Right , quantification of the cytosolic DELE1 S -mClover from n = 2 blots. (b) Accumulation of DELE1 S is protein-synthesis independent. Biochemical fractionation of cells stably expressing DELE1-mClover treated with 1.25 ng/mL oligomycin (Oli) and 20 mug/mL cycloheximide (CHX) for 4 h where indicated. Left , representative immunoblot of the cytosolic (C) and mitochondrial (M) fractions. OMA1 as probed as mitochondrial marker. Right , quantification of the cytosolic DELE1 S -mClover from n = 2 blots. (c) Transient overexpression (OE) of the cytosolically localized DELE1(DeltaN206), but not the DELE1(DeltaN275) construct induces the ATF4 reporter. Knockdown (KD) of HRI blocks reporter activation (mean +- s.d., n = 3 culture wells). (d) Co-immunoprecipitation of HRI with transiently expressed full-length DELE1-mClover but not with DELE1(DeltaN275)-mClover. Similar results in n = 2 independent experiments. (e,f) HRI enzyme kinetics in the presence or absence of DELE1 with or without 5 muM hemin using different concentrations of the substrate eIF2alpha. (e) Representative immunoblot. (f) Quantification and fitting to

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Salubrinal inhibited cell growth and migration in cancer cells. Three cancer cell lines (MDA-MB-231, AGS, and SAS) were treated with or without 30 muM of salubrinal in normal culture medium. ( A ) The protein levels of eIF2alpha, p-eIF2alpha, and ATF4 were detected using Western blotting after salubrinal treatment for 24 h; The value of the control group was set as 1. ( B ) The cell growth rate at 0, 24, 48, and 72 h after salubrinal treatment was detected by a sulforhodamine B (SRB) assay. ( C ) The colony formation ability was checked after treatment with or without salubrinal for 10 days in MDA-MB-231 cells, for 7 days in AGS cells, and for 9 days in SAS cells. ( D ) The ability of cell migration was detected using a transwell migration assay. After salubrinal pre-treatment for 24 h, the migration time was found to be 6 h for MDA-MB-231 cells, 8 h for AGS cells, and 24 h for SAS cells. The photograph was taken by a microscope (100x magnification). The data are presented as the means +-SEMs of the results from three independent experiments. * p < 0.05. Sal: salubrinal.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 7 BIRD-2-triggered apoptosis is reduced by depleting the ER Ca 2+ store in SU-DHL-4 cells. a Analysis of the cytosolic Ca 2+ response in SU-DHL-4 cells using Fura-2 AM. After the addition of 3 mM EGTA, 1 or 10 uM TG or 10 uM CPA were added to deplete the ER Ca 2+ store. The curves represent the mean +- SEM of three independent experiments. The TG/CPA-releasable Ca 2+ is quantified by measuring the AUC ( F 340 / F 380 x s), which is shown in b . c Representative scatter plots from flow cytometry analysis detecting apoptosis in SU-DHL-4 cells stained with Annexin V-FITC and 7-AAD. Cells were pre-treated with or without 1 uM TG 30 min prior to application of 10 uM BIRD-2. After 2 h of BIRD-2 treatment, apoptotic cell death was detected by measuring the Annexin V-FITC-positive fraction. d Quantitative analysis of five independent experiments detecting apoptosis in SU-DHL-4 cells treated for 2 h with 10 uM BIRD-2, with or without a pre-treatment of 30 min with 1 uM TG. e Quantitative analysis of five independent experiments detecting apoptosis in SU-DHL-4 cells treated for 2 h with 10 uM BIRD-2, with or without a pre-treatment of 30 min with 10 uM CPA. f A representative western blot of four independent experiments showing the expression levels of total eIF2alpha and p-eIF2alpha in SU-DHL-4 cells treated for 4 h with 5ug/ml tunicamycin. The expression level of vinculin was used as a loading control. g Quantification of the p-eIF2alpha/total eIF2alpha-protein

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 7 Irp2 deficiency impairs Fe-S cluster protein function and causes ER stress. a CRISPR/Cas9 depletion of Irp2 in INS-1 832/13 cells (sgIrp2.1, sgIrp2.2) and control parental cells grown in the presence of FAC (10 µg/mL), DFO (50 µM), or no treatment (NT) for 18 h. Irp2, Fth1, Ftl1 and TfR1 were assessed by western blot analysis to show efficacy of Irp2 knockdown and appropriate iron regulation. beta-Actin is a loading control. Asterisk, nonspecific band. b The total iron content measured by ICP-MS and normalized to total cellular protein ( n = 3 independent biological experiments). c , d Mitochondrial ( c ) and cytosolic ( d ) aconitase activity in control, sgIrp2.1, and sgIrp2.2 INS-1 cells grown in medium with or without supplemental FAC and normalized to total cellular protein. e , f Complex I activity ( e ) and complex IV activity ( f ) in lysates from control EV and shIrp2 cells grown in medium with or without supplemental FAC and normalized to total cellular protein ( n >= 3 independent biological experiments). g ATP production in control INS-1, sgIrp2.1, and sgIrp2.2 cells grown in medium with or without supplemental FAC and assayed under basal (5 mM) glucose and after stimulation with 15 mM glucose for 1 h. ATP production was normalized to total cellular protein ( n = 5 independent biological experiments). h Western blot analysis of eIF2alpha-P, eIF2alpha-total, and Grp78/BiP levels in sgIrp2.1 and sgIrp2.2 cells under basal glucose (5

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 Western blot results using samples generated via the Rapid Protein Extraction (RPE) Method. A) MEFs were grown in cell culture flasks to

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 3 Further testing of the Rapid Protein Extraction (RPE) Method. A) Gcn2 +/+ MEF cells were grown in medium with or without 2 muM MG132 for 1 h, and then incubated in medium containing puromycin for 10 min prior to harvesting. 10 mul of samples were subjected to immunoblotting with anti-puromycin antibodies (1:5000, Millipore-MABE343, clone 12D10) [ 7 ] and, after stripping [ 10 ], with anti-actin antibodies, as described in [ 5 ]. Molecular markers are depicted in kDa on the left side of the image. B) 5 x 10 5 human (SKBR3) or mouse (4T1) breast cancer cell lines were each grown overnight in 6 cm plastic dishes containing 4 ml RPMI 1640 medium (Gibco Thermo Fisher Scientific, # 72400-047), supplemented with FBS, sodium pyruvate and antibiotics as above. After subjecting cells to the RPE method, 20 mul and 5 mul of the cell extract were resolved via SDS-PAGE in 6% (for detecting GCN2 and Gcn2-P, 20 mul equate to ~50 mug of total protein loaded) and 10% (eIF2alpha and eIF2alpha-P, 5 mul equate to ~12.5 mug of total protein loaded) denaturing Tris acrylamide gels, followed by immunoblotting to detect the indicated proteins. Working solutions containing primary antibodies were diluted in standard Tris buffered saline containing 5% (w/v) skim milk powder, or 3% (w/v) BSA (for eIF2alpha-P antibodies, BSA fraction-V IgG-free, Gibco Thermo Fisher Scientific, # 30063721). Primary antibodies were detected with horseradish peroxidase (HRP) conjugated to goat anti-rabbit antibodie